Samlyn Capital, LLC Argenx Se Transaction History

Samlyn Capital, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$248.13 - $308.36 $20.3 Million - $25.3 Million	-81,965 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$215.51 - $272.51 $11.9 Million - $15 Million	-55,100 Reduced 40.2%	81,965 $21.5 Million
Q2 2020 Aug 14, 2020	BUY	$127.44 - $232.72 $6.33 Million - $11.6 Million	49,643 Added 56.79%	137,065 $30.9 Million
Q1 2020 May 15, 2020	BUY	$108.83 - $165.23 $9.51 Million - $14.4 Million	87,422 New	87,422 $11.5 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.6B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Samlyn Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Samlyn Capital, LLC with notifications on news.